PCIDB

KNApSAcK Metabolite C00030399

Metabolite

KNApSAcK Entry

id C00030399
Name Panaxoside Rg2 / Ginsenoside Rg2
CAS RN 52286-74-5
Standard InChI InChI=1S/C42H72O13/c1-20(2)11-10-14-42(9,51)22-12-16-40(7)28(22)23(44)17-26-39(6)15-13-27(45)38(4,5)35(39)24(18-41(26,40)8)53-37-34(32(49)30(47)25(19-43)54-37)55-36-33(50)31(48)29(46)21(3)52-36/h11,21-37,43-51H,10,12-19H2,1-9H3/t21-,22-,23+,24-,25+,26+,27-,28-,29-,30+,31+,32-,33+,34+,35-,36-,37+,39+,40+,41+,42-/m0/s1
Standard InChI (Main Layer) InChI=1S/C42H72O13/c1-20(2)11-10-14-42(9,51)22-12-16-40(7)28(22)23(44)17-26-39(6)15-13-27(45)38(4,5)35(39)24(18-41(26,40)8)53-37-34(32(49)30(47)25(19-43)54-37)55-36-33(50)31(48)29(46)21(3)52-36/h11,21-37,43-51H,10,12-19H2,1-9H3

Cluster

Phytochemical cluster No. 51
KCF-S cluster No. 32

Link

ChEMBL

By standard InChI CHEMBL505747
By standard InChI Main Layer CHEMBL505747 CHEMBL1095005 CHEMBL1095006 CHEMBL1475728

KEGG

By LinkDB

CTD

By CAS RN C026474

Human Protein / Gene in interaction

5 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P11387 DNA topoisomerase 1 Isomerase CHEMBL1095005 CHEMBL1095006 CHEMBL1111926 (2)
0 / 0
P11388 DNA topoisomerase 2-alpha Isomerase CHEMBL1095005 CHEMBL1095006 CHEMBL1111927 (2)
0 / 0
O75496 Geminin Unclassified protein CHEMBL1475728 CHEMBL2114843 (1)
0 / 0
Q9Y468 Lethal(3)malignant brain tumor-like protein 1 Unclassified protein CHEMBL1475728 CHEMBL1614280 (1)
0 / 0
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL1475728 CHEMBL1738588 (1)
0 / 0

CTD interaction (16)

compound gene gene name gene description interaction interaction type form reference
pmid
C026474 200186 CRTC2
TORC-2
TORC2
CREB regulated transcription coactivator 2 [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein decreases activity
/ increases activity
protein 22062806
C026474 92579 G6PC3
SCN4
UGRP
glucose 6 phosphatase, catalytic, 3 (EC:3.1.3.9) (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA] decreases expression
/ decreases reaction
mRNA 22062806
C026474 92579 G6PC3
SCN4
UGRP
glucose 6 phosphatase, catalytic, 3 (EC:3.1.3.9) ginsenoside Rg2 results in decreased expression of G6PC3 mRNA decreases expression
mRNA 22062806
C026474 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] decreases reaction
/ increases phosphorylation
protein 22062806
C026474 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) ginsenoside Rg2 results in increased phosphorylation of GSK3B protein increases phosphorylation
protein 22062806
C026474 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose affects cotreatment
/ decreases chemical synthesis
/ increases expression
/ increases phosphorylation
protein 22062806
C026474 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 ginsenoside Rg2 results in increased activity of NR0B2 protein increases activity
protein 22062806
C026474 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein decreases activity
/ increases activity
protein 22062806
C026474 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 ginsenoside Rg2 results in increased expression of NR0B2 mRNA increases expression
mRNA 22062806
C026474 8431 NR0B2
SHP
SHP1
nuclear receptor subfamily 0, group B, member 2 [[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose affects cotreatment
/ decreases chemical synthesis
/ increases expression
/ increases phosphorylation
mRNA 22062806
C026474 5105 PCK1
PEPCK-C
PEPCK1
PEPCKC
phosphoenolpyruvate carboxykinase 1 (soluble) (EC:4.1.1.32) (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [ginsenoside Rg2 results in decreased expression of PCK1 mRNA] decreases expression
/ decreases reaction
mRNA 22062806
C026474 5105 PCK1
PEPCK-C
PEPCK1
PEPCKC
phosphoenolpyruvate carboxykinase 1 (soluble) (EC:4.1.1.32) ginsenoside Rg2 results in decreased expression of PCK1 mRNA decreases expression
mRNA 22062806
C026474 10891 PPARGC1A
LEM6
PGC-1(alpha)
PGC-1v
PGC1
PGC1A
PPARGC1
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA] decreases expression
/ decreases reaction
mRNA 22062806
C026474 10891 PPARGC1A
LEM6
PGC-1(alpha)
PGC-1v
PGC1
PGC1A
PPARGC1
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA decreases expression
mRNA 22062806
C026474 6794 STK11
LKB1
PJS
hLKB1
serine/threonine kinase 11 (EC:2.7.11.1) (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein] decreases reaction
/ increases phosphorylation
protein 22062806
C026474 6794 STK11
LKB1
PJS
hLKB1
serine/threonine kinase 11 (EC:2.7.11.1) ginsenoside Rg2 results in increased phosphorylation of STK11 protein increases phosphorylation
protein 22062806

Related Disease

Diseases related to CTD interactions

2 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D019970 C026474 Cocaine-Related Disorders therapeutic
10418781
D006948 C026474 Hyperkinesis therapeutic
10418781